GSK plc
GSK
$37.56
$0.411.10%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.26% | 1.39% | 3.93% | 1.08% | 10.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.26% | 1.39% | 3.93% | 1.08% | 10.69% |
| Cost of Revenue | 11.14% | -0.21% | 11.87% | 6.67% | 9.17% |
| Gross Profit | 5.89% | 1.95% | 0.68% | -1.05% | 11.24% |
| SG&A Expenses | -0.30% | 3.39% | 3.65% | 75.03% | -0.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.18% | -18.40% | 130.93% | 62.32% | 32.81% |
| Total Operating Expenses | 6.26% | 0.99% | 15.58% | 40.27% | 7.05% |
| Operating Income | 9.58% | 2.29% | -39.57% | -75.21% | 20.11% |
| Income Before Tax | 33.66% | 54.52% | 53.15% | -96.33% | -24.17% |
| Income Tax Expenses | 33.61% | 21.80% | 436.43% | -100.40% | -20.46% |
| Earnings from Continuing Operations | 33.66% | 62.81% | 29.78% | -95.64% | -24.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -64.09% | -320.00% | -86.87% | -80.60% | -9.11% |
| Net Income | 30.27% | 54.21% | 21.95% | -104.07% | -27.21% |
| EBIT | 9.58% | 2.29% | -39.57% | -75.21% | 20.11% |
| EBITDA | 27.00% | 11.44% | -18.37% | -50.27% | 24.23% |
| EPS Basic | 30.76% | 53.47% | 21.18% | -104.05% | -27.67% |
| Normalized Basic EPS | 5.42% | -5.06% | -48.50% | -85.83% | 22.54% |
| EPS Diluted | 30.43% | 53.68% | 20.94% | -104.10% | -27.65% |
| Normalized Diluted EPS | 5.29% | -5.19% | -48.55% | -85.84% | 22.44% |
| Average Basic Shares Outstanding | -0.39% | 0.47% | 0.62% | 0.62% | 0.64% |
| Average Diluted Shares Outstanding | -0.29% | 0.58% | 0.70% | 0.71% | 0.71% |
| Dividend Per Share | 12.95% | 5.94% | 3.12% | 10.10% | 7.99% |
| Payout Ratio | -0.18% | -0.31% | -0.09% | -28.24% | 0.62% |